COSMIC Actionability v8 - release notes

COSMIC Actionability is a vital tool for anyone working in precision oncology. Our expertly curated database details the availability and development of drugs targeting somatic mutations in cancer. We integrate data from case studies, clinical trials, and regulatory bodies to represent a full picture of the current precision oncology pipeline.

Actionability has three core units: mutation, disease and drug. By capturing relations between these units, we identify existing and upcoming drugs that target specific genetic variants in different cancer types.

COSMIC's trusted expert-curation process is embedded within Actionability, but it exists as a standalone product. Releases of Actionability occur more frequently than COSMIC to better reflect the rapid pace of global precision oncology. Actionability is a cutting edge ' living-tool' and the data is intended to be as up to date as possible.

Actionability downloads are free for Academic Non-Commercial Use* via COSMIC or available to purchase and download from QIAGEN. A taster file of EGFR data can be accessed here

If you'd like to know more about the curation process behind Actionability, read our interview with Principal Curator, Steve Jupe

**Please see full terms and conditions of commercial and non-commercial use on our licensing pages.*

Updates

COSMIC Actionability v8 includes **22** additional fully-curated genes:
ATR, BCL2, CD33, CDKN2A, CHEK2, ERBB4, FBXW7, GNAS, MAP2K2, MTOR, MYD88, NOTCH1, NTRK1, NTRK2, NTRK3, PALB2, PIK3CB, PTPN11, RAF1, SYK, TERT, VHL

This means we have a total of **94** fully curated genes:

ABL1, AKT1, AKT2, AKT3, ALK, AR, ASXL1, ATM, ATR, BCL2, BCR, BRAF, BRCA1, BRCA2, BTK, CD274 (PD-L1), CD33, CDK12, CDK4, CDK6, CDKN2A, CEBPA, CHEK2, CTNNB1, DDR2, DNMT3A, EGFR, ERBB2, ERBB3, ERBB4, ETV6, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FOXL2, GNA11, GNAS, GNAQ, HRAS, IDH1, IDH2, JAK1, JAK2, JAK3, KIT, KMT2A, KRAS, MAP2K1 (MEK1), MAP2K2, MDM2, MDM4, MET, MLH, MPL, MSH2, MSH6, MTOR, MYD88, NF1, NF2, NOTCH1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PMS2, PTCH1, PTEN, PTPN11, RAF1, RET, ROS1, RUNX1, SF3B1, SMAD4, SMO, STK11, SYK, TERT, TET2, TP53, TSC1, VHL, WT1

To view the full list of curated genes visit the About page on the Actionability website.
All previously-recorded clinical trials have been checked for new or updated results.

Actionability statistics - v8

Genes fully curated	**94**
Genes included	**357**
Drugs	**1686**
Treatment combinations	**4311**
Trials with results	**3977**
Trials with no results	**5431**
Total trials	**9408**
Evidence from trial databases	**6721**
Evidence from PubMed & others	**2855**
Total sources	**9576**
Point mutations	**154**
Total variants	**804**

Accessing Actionability - T&Cs

From v7 Actionability and all subsequent releases will be freely available for non-commercial use. Please see our terms for clarification on commercial/non-commercial use.

Please make sure you read and understand whether you count as commercial via our licensing page

If you are using COSMIC Actionability for non-commercial purposes, you can register for an account and download the data directly from COSMIC (https://cancer.sanger.ac.uk/cosmic/download)

To access COSMIC Actionability for commercial use, please contact our Sales Partner QIAGEN